ACCESSWIRE
23 Nov 2022, 21:55 GMT+10
LUND, SE / ACCESSWIRE / November 23, 2022 / BioInvent International (STO:BINV)
Lund, Sweden, November 23, 2022 - BioInvent International AB ('BioInvent') (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, invites investors, analysts and media to an R&D Day in Stockholm on Thursday December 8, 2022.
The program will start at 2:00 pm CET, with registration from 1:00 pm CET and will end with networking at around 4:30 pm CET. The event will take place at Epicenter, entrance at Regeringsgatan 61A in Stockholm. Moderator for the day is Lars Frick, journalist at Börsveckan.
The R&D Day will feature KOL Dr Sean Lim from University Hospital Southampton, who will discuss the current treatment landscape and unmet medical need in treating patients with T cell lymphomas. Representatives from BioInvent's management team will provide an update on BioInvent's broad clinical pipeline with five programs in ongoing clinical development.
Agenda BioInvent R&D Day December 8, 2022
The event will be conducted in English and there will be a simultaneous live webcast for those unable to attend in person. The webcast, with presentation slides, will be available to view on BioInvent's website www.bioinvent.com and a recording will be made available shortly after the event.
If you wish to register to participate in the event on site, please send an email to anmalan@bioinvent.com with the subject 'R&D Dec 8' (RSVP December 2).
Dr Sean Lim is an Associate Professor and Honorary Consultant in Hematological Oncology at University Hospital Southampton, United Kingdom. Dr Lim is a practicing clinician specializing in lymph node cancers and she also leads a scientific research group focusing on the development of new anti-cancer drugs, in particular novel therapeutic monoclonal antibodies.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Attachments
Invitation to BioInvent's R&D Day in Stockholm on December 8, 2022
SOURCE: BioInvent International
Get a daily dose of Pennsylvania Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Pennsylvania Sun.
More InformationWASHINGTON, D.C.: Finland and Sweden are prepared to join the NATO alliance, the U.S. State Department announced this week.The move ...
WASHINGTON D.C.: The US Justice Department has filed an antitrust complaint claiming that Google is abusing its dominance in digital ...
Public health experts have welcomed Mexico's ban on cigarette smoking in all public places, including hotels and beaches, after the ...
YONKERS, New York: After testing discovered harmful levels of heavy metals in chocolate, consumer magazine Consumer Reports has urged four ...
OUAGADOUGOU, Burkina Faso: As Burkina Faso, in western Africa, faces an Islamist insurgency, it is set to end a military ...
TOKYO, Japan: Japanese Prime minister Fumio Kishida said this week that it was "now or never" for Japan, one of ...
BENTONVILLE, Arkansas: To attract and retain employees in a tight domestic labor market, Walmart has announced that it it will ...
NEW YORK, New York - U.S. stocks hesitatingly continued higher Friday, reflecting widespread gains, albeit modest ones, across the globe."We're ...
NEW YORK CITY, New York: As early as this year, lab-grown meat could be served in some restaurants in the ...
BANGKOK, Thailand: Following China's reopening and the end of its strict COVID-19 restrictions, businesses on Thailand's holiday island of Phuket ...
NEW YORK, New York - Recession fears faded on Wall Street Thursday as annualized 4th quarter GDP (gross domestic product) ...
WASHINGTON D.C.: In December 2022, US existing home sales declined to a 12-year low, but lower mortgage rates raised cautious ...